OncoTargets and Therapy · 2016 · 55 citations · 55 references
MedicineOncologyPathologyBreast OncologyMolecular OncologyTumor ProgressionAngiogenesisAngiogenesis In CancerBreast PathologyMolecular Tumor ProfilingTumor MarkersTumor-associated AntigensBenign Breast NeoplasmsBenign Breast TumorsCancer Antigen 15-3Diagnostic SensitivityMatrix Metalloproteinase InhibitorsPositive Predictive ValueTumor Marker AnalysisTumor Marker Assays
Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 may play a role in the pathogenesis of cancer disease. We investigated their levels and utility in comparison to cancer antigen (CA) 15-3 in patients with breast cancer (BC) and in relation to the control groups. The study included 100 women with BC, 50 patients with benign breast tumor, and 50 healthy women. The plasma levels of the tested parameters were determined using enzyme-linked immunosorbent assay, while CA 15-3 with chemiluminescent microparticle immunoassay. The results demonstrated significant differences in the concentration of the tested parameters and CA 15-3 between groups of patients with BC and healthy patients or patients with benign breast tumor. The plasma levels of VEGF and tissue inhibitor of metalloproteinase-1 were significantly higher in advanced tumor stages. The tested parameters were comparable to CA 15-3 values of the diagnostic sensitivity, specificity, the predictive values of positive and negative test results, and the area under the receiver-operating characteristic curve. The combined use of the tested parameters with CA 15-3 resulted in the increase in sensitivity, negative predictive value, and area under the receiver-operating characteristic curve, especially in the combination of VEGF with tumor marker (84%, 73%, 0.888, respectively). These findings suggest the usefulness of the tested parameters in the diagnosis of BC. VEGF, especially in combination with CA 15-3, showed the highest usefulness in the diagnosis of early BC.
55
Molecular Profiling of Inflammatory Breast Cancer
Ivan Bièche, Florence Lerebours, Sengül Tozlu et al. · Clinical Cancer Research · 2004 · 255 citations · Full text
MMP-9 expression varies according to molecular subtypes of breast cancer
Einas Yousef, Muhammad Tahir, Yves St‐Pierre et al. · BMC Cancer · 2014 · 190 citations · Full text